The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Platinum Compounds: a New Class of Potent Antitumour Agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Self-citationRosenberg, B., Van Camp, L., Grimley, E. B., & Thomson, A. J. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96186-7 · Cited by 420
Self-citationPlatinum-Induced Filamentous Growth in Escherichia coli
Rosenberg, B., Renshaw, E., Vancamp, L., Hartwick, J., & Drobnik, J. (1967) · Journal of Bacteriology · doi:10.1128/jb.93.2.716-721.1967 · Cited by 212
Self-citationZur experimentellen Therapie der Tumoren
Collier, W. A., & Krauß, F. (1931) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01625394 · Cited by 17
Cited by
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Metallodrugs in Medicinal Inorganic Chemistry
Mjos, K. D., & Orvig, C. (2014) · Chemical Reviews · doi:10.1021/cr400460s · Cited by 1,289
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Block copolymer micelles for drug delivery: Design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.013 · Cited by 783
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Dhar, S., Liu, Z., Thomale, J., Dai, H., & Lippard, S. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803036e · Cited by 700
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2014) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 630
Platinum(IV) antitumour compounds: their bioinorganic chemistry
Hall, M. D., & Hambley, T. W. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00026-7 · Cited by 622
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Reedijk, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737293100 · Cited by 617
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Cisplatin resistance and opportunities for precision medicine
Amable, L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.001 · Cited by 589
Zheng, M., Liu, S., Li, J., Qu, D., Zhao, H., Guan, X., Hu, X., Xie, Z., Jing, X., & Sun, Z. (2014) · Advanced Materials · doi:10.1002/adma.201306192 · Cited by 588
Cellular Responses to Cisplatin‐Induced DNA Damage
Basu, A., & Krishnamurthy, S. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/201367 · Cited by 569
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Hypoxia-targeted drug delivery
Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 542
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Charles F. Kettring prize. Fundamental studies with cisplatin
Rosenberg, B. (1985) · Cancer · doi:10.1002/1097-0142(19850515)55:10<2303::aid-cncr2820551002>3.0.co;2-l · Cited by 517
Self-citationMetal-based anticancer chemotherapeutic agents
Muhammad, N., & Guo, Z. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.02.003 · Cited by 515
Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011379108 · Cited by 513
Dhar, S., Daniel, W. L., Giljohann, D. A., Mirkin, C. A., & Lippard, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9071282 · Cited by 510
Jeyaraj, M., Gurunathan, S., Qasim, M., Kang, M.-H., & Kim, J.-H. (2019) · Nanomaterials · doi:10.3390/nano9121719 · Cited by 481
Makovec, T. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0018 · Cited by 480
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity
Karasawa, T., & Steyger, P. S. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.06.012 · Cited by 475
Application of ferrocene and its derivatives in cancer research
Ornelas, C. (2011) · New Journal of Chemistry · doi:10.1039/c1nj20172g · Cited by 473
Metal complex interactions with DNA
Pages, B. J., Ang, D. L., Wright, E. P., & Aldrich-Wright, J. R. (2015) · Dalton Transactions · doi:10.1039/c4dt02700k · Cited by 459
Platinum nanoparticles in nanobiomedicine
Pedone, D., Moglianetti, M., De Luca, E., Bardi, G., & Pompa, P. P. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00152e · Cited by 454
Madias, N. E., & Harrington, J. T. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90825-2 · Cited by 453
Cisplatin: a review of toxicities and therapeutic applications
Barabas, K., Milner, R., Lurie, D., & Adin, C. (2008) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00142.x · Cited by 446
Therrien, B., Süss‐Fink, G., Govindaswamy, P., Renfrew, A. K., & Dyson, P. J. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800186 · Cited by 446
Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA
Pinto, A. L., & Lippard, S. J. (1985) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(85)90001-0 · Cited by 437
Multiplicity of metal ion binding patterns to nucleobases
Lippert, B. (2000) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(00)00260-5 · Cited by 430
Carbohydrates as ligands: coordination equilibria and structure of the metal complexes
Gyurcsik, B., & Nagy, L. (2000) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(99)00183-6 · Cited by 428
Meier-Menches, S. M., Gerner, C., Berger, W., Hartinger, C. G., & Keppler, B. K. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00332c · Cited by 425
Knoll, J. D., & Turro, C. (2015) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.05.018 · Cited by 423
The Mechanism of Action of Antitumor Platinum Compounds
Roberts, J. J., & Thomson, A. J. (1979) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60799-0 · Cited by 411
Carbon Nanohorns as Anticancer Drug Carriers
Ajima, K., Yudasaka, M., Murakami, T., Maigné, A., Shiba, K., & Iijima, S. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0500566 · Cited by 411
Cisplatin (cis-diamminedichloroplatinum II)
Prestayko, A. W., D'Aoust, J. C., Issell, B. F., & Crooke, S. T. (1979) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(79)80057-2 · Cited by 405
New Cisplatin Analogues in Development: A Review
Weiss, R. B., & Christian, M. C. (1993) · Drugs · doi:10.2165/00003495-199346030-00003 · Cited by 404
Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives
Lee, S. Y., Kim, C. Y., & Nam, T.-G. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s275007 · Cited by 400
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.139 · Cited by 399
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
DNA repair mechanisms in cancer development and therapy
Torgovnick, A., & Schumacher, B. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00157 · Cited by 396
Nanocarrier-based systems for targeted and site specific therapeutic delivery
Majumder, J., Taratula, O., & Minko, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.010 · Cited by 394
Bioactive Luminescent Transition‐Metal Complexes for Biomedical Applications
Ma, D., He, H., Leung, K., Chan, D. S., & Leung, C. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208414 · Cited by 388
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Brabec, V., & Nováková, O. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.05.002 · Cited by 384
Romani, A. M. P. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115323 · Cited by 383
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Fennell, D. A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382
Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes
Kapdi, A. R., & Fairlamb, I. J. S. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00063c · Cited by 379
Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
dos Santos, N. A. G., Carvalho Rodrigues, M. A., Martins, N. M., & dos Santos, A. C. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0821-7 · Cited by 378
Platinum coordination complexes in cancer chemotherapy
Rosenberg, B. (1973) · Die Naturwissenschaften · doi:10.1007/bf00623551 · Cited by 374
Self-citationWhat do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Dhar, S., & Lippard, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912276106 · Cited by 369
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Guo, Z., & Sadler, P. J. (1999) · Advances in Inorganic Chemistry · doi:10.1016/s0898-8838(08)60271-8 · Cited by 354
Platinum Drug Distribution in Cancer Cells and Tumors
Klein, A. V., & Hambley, T. W. (2009) · Chemical Reviews · doi:10.1021/cr9001066 · Cited by 351
Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs
Liu, W., & Gust, R. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.09.004 · Cited by 351
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
The influence of structure on the activity and toxicity of Pt anti-cancer drugs
Hambley, T. W. (1997) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(97)00023-4 · Cited by 348
Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention
Schacht, J., Talaska, A. E., & Rybak, L. P. (2012) · The Anatomical Record · doi:10.1002/ar.22578 · Cited by 348
Richardson, D., Tran, E., & Ponka, P. (1995) · Blood · doi:10.1182/blood.v86.11.4295.bloodjournal86114295 · Cited by 345
Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design
Reedijk, J. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200900054 · Cited by 343
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
de Biasi, A. R., Villena-Vargas, J., & Adusumilli, P. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1298 · Cited by 342
Advances in cobalt complexes as anticancer agents
Munteanu, C. R., & Suntharalingam, K. (2015) · Dalton Transactions · doi:10.1039/c5dt02101d · Cited by 330
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_21 · Cited by 330
Platinum‐based anticancer agents: Innovative design strategies and biological perspectives
Ho, Y., Au‐Yeung, S. C. F., & To, K. K. W. (2003) · Medicinal Research Reviews · doi:10.1002/med.10038 · Cited by 329
Petsko, G. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.538 · Cited by 327
Hydrolysis Theory for Cisplatin and Its Analogues Based on Density Functional Studies
Zhang, Y., Guo, Z., & You, X.-Z. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0023938 · Cited by 317
Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy
Dasari, S., Njiki, S., Mbemi, A., Yedjou, C. G., & Tchounwou, P. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031532 · Cited by 308
Bioactive iridium and rhodium complexes as therapeutic agents
Leung, C.-H., Zhong, H.-J., Chan, D. S.-H., & Ma, D.-L. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.01.034 · Cited by 303
Metal complexes in medicinal chemistry: new vistas and challenges in drug design
Thompson, K. H., & Orvig, C. (2006) · Dalton Trans. · doi:10.1039/b513476e · Cited by 298
Pierroz, V., Joshi, T., Leonidova, A., Mari, C., Schur, J., Ott, I., Spiccia, L., Ferrari, S., & Gasser, G. (2012) · Journal of the American Chemical Society · doi:10.1021/ja307288s · Cited by 296
Baik, M.-H., Friesner, R. A., & Lippard, S. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036960d · Cited by 293
Platinum(iv) anticancer prodrugs – hypotheses and facts
Gibson, D. (2016) · Dalton Transactions · doi:10.1039/c6dt01414c · Cited by 286
Arnesano, F., & Natile, G. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.01.028 · Cited by 282
Organelle-targeting metal complexes: From molecular design to bio-applications
Qiu, K., Chen, Y., Rees, T. W., Ji, L., & Chao, H. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.10.022 · Cited by 280
Skubitz, K. M., & D'Adamo, D. R. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1409 · Cited by 277
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 276
l‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth
Oda, K., Hosoda, N., Endo, H., Saito, K., Tsujihara, K., Yamamura, M., Sakata, T., Anzai, N., Wempe, M. F., Kanai, Y., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01386.x · Cited by 273
Casini, A., Hartinger, C., Gabbiani, C., Mini, E., Dyson, P. J., Keppler, B. K., & Messori, L. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.11.003 · Cited by 267
On the mechanism of the antitumor activity of ferrocenium derivatives
Osella, D., Ferrali, M., Zanello, P., Laschi, F., Fontani, M., Nervi, C., & Cavigiolio, G. (2000) · Inorganica Chimica Acta · doi:10.1016/s0020-1693(00)00147-x · Cited by 266
Encapsulation of Pt(iv) prodrugs within a Pt(ii) cage for drug delivery
Zheng, Y.-R., Suntharalingam, K., Johnstone, T. C., & Lippard, S. J. (2015) · Chemical Science · doi:10.1039/c4sc01892c · Cited by 265
Phototherapeutic anticancer strategies with first-row transition metal complexes: a critical review
Gourdon, L., Cariou, K., & Gasser, G. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00609f · Cited by 262
Complexes of metals other than platinum as antitumour agents
K�pf-Maier, P. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00193472 · Cited by 261
Nishiyama, N., Yokoyama, M., Aoyagi, T., Okano, T., Sakurai, Y., & Kataoka, K. (1999) · Langmuir · doi:10.1021/la980572l · Cited by 259
New trends in platinum and palladium complexes as antineoplastic agents
Fanelli, M., Formica, M., Fusi, V., Giorgi, L., Micheloni, M., & Paoli, P. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.11.004 · Cited by 258
Fluorescent Conjugated Polyelectrolytes for Bioimaging
Pu, K., & Liu, B. (2011) · Advanced Functional Materials · doi:10.1002/adfm.201101153 · Cited by 257
Metadata
- Authors
- ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H.
- Venue
- Nature
- Published
- 1969-04
- Volume
- 222
- Issue
- 5191
- Pages
- 385-386
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012108057
- Cited by
- 3,972
- References
- 4
- FWCI
- 16.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.